Arjuna invests in curcumin clinical study

ARJUNA Natural Ltd is investing 10 percent of its total turnover, or US$1.5 million to a clinical research program focusing on the health benefits of its turmeric curcumin, a potent antioxidant, as well as other new healthy ingredients scheduled to be released in 2016.

“We differentiate our turmeric curcumin through a practice of extensive research and development,” said Benny Antony, PhD, Joint Managing Director for Arjuna. “BCM-95 is the most researched bioavailable curcumin on the market, with a majority share in the US.”

Research is being conducted at universities and institutes in India, Australia, Italy, the US and Japan on Arjuna’s leading all-natural curcumin, the BCM-95®. Twelve clinical studies of turmeric curcumin, covering a range of conditions that include depression, Alzheimer disease, cancer and others, are ongoing. Arjuna holds 12 patents for BCM-95 worldwide, and has several additional patents pending.

(Photo: Arjuna)

Arjuna’s curcumin is highly bioavailable as a result of the synergism between the curcumin and the compound ar-turmerone, an essential oil component of turmeric.

The patented formulation method, produced in Arjuna’s own facility, involves extracting the maximum amount of free curcumin, without synthetic additives. All raw materials used are completely traceable. This ensures BCM-95 is the most trusted bioavailable source of curcumin. Two dozen studies support the health benefits of BCM-95 Curcumin extract.

“Arjuna meets the new European 2015/1933 PAH regulation that sets maximum levels of PAHs in food supplements,” said Mr Antony. “This bioactive ingredient is clean of pesticides and heavy metals. Arjuna invested in the most advanced quality control equipment to meet the new EU regulations, and to ensure all products are clean and safe. The growing global demand for curcumin, and consumer expectations of pure formulations, encouraged Arjuna to develop a clean, GMO-free ingredient that consumers can trust.”

Arjuna’s R&D center consists of 40 scientists, comprising 10 percent of its workforce, and with women occupying 50 percent of lead positions. The scientists work full-time in bench research and monitoring clinical studies for various applications in the dietary supplement and pharmaceutical industries.

Arjuna will present the most recent clinical study results on curcumin for mental health disorders at the Vitafoods, Europe conference, 10 - 12 May 2016 in Geneva. Its production processes and products meet market-specific regulations worldwide. A GMP-certified, SAP-driven company, Arjuna has achieved international certifications including ISO22000, Kosher and Halal. Arjuna continues to engage in research and development, with continuing scientific validation of its novel product line through advanced clinical studies.